сгенерировать QR код
Открытый доступ
Только для подписчиков
Профилактика тромбозов в онкогинекологии
https://doi.org/10.30629/0023-2149-2024-102-11-12-824-830
Аннотация
В представленном обзоре иностранной литературы затрагивается актуальный вопрос профилактики венозных тромбоэмболических осложнений в практике современных онкогинекологов, подчеркивается связь между тяжестью течения онкологического процесса и частотой тромбоэмболических осложнений, наличие которых предопределяет неблагоприятный исход; обсуждаются методики профилактического применения антикоагулянтов, их место в комплексной терапии и взаимодействие с другими методами проводимого лечения. В данной работе обсуждаются лабораторные методики для определения маркеров онкологических заболеваний и контроля проводимого лечения. Рассматривается перспектива мультидисциплинарного подхода с участием генетиков, иммунологов, биохимиков и специалистов лабораторной диагностики к решению вопросов профилактики и лечения онкогинекологических заболеваний.
Об авторах
А. П. Мельников
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии» им. академика В.И. Краснопольского
Россия
Россия
Мельников Андрей Павлович — канд. мед. наук, врач АФО ГБУЗ МО МОНИИАГ им. акад. В.И. Краснопольского
Москва
Е. И. Московкина
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии» им. академика В.И. Краснопольского
Россия
Россия
Московкина Евгения Ивановна — клинический ординатор
Москва
К. С. Гасанова
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии» им. академика В.И. Краснопольского
Россия
Россия
Гасанова Камилла Сулеймановна — клинический ординатор
Москва
Список литературы
1. Zhu Y.W., Feng T.B., Zhou X.J., Hu X.L., Ding J., Zhu W.Y., Qian D.P., Sun Y.W. Routine hemostasis and hemogram parameters: valuable assessments for coagulation disorder and chemotherapy in cancer patients. Chin. Med. J. (Engl). 2016;129(15):1772–7. DOI: 10.4103/0366-6999.186637
2. Ohashi Y., Ikeda M., Kunitoh H., Sasako M., Okusaka T., Mukai H.et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn. J. Clin. Oncol. 2020;50(11):1246–1253. DOI: 10.1093/jjco/hyaa112
3. Dring J.C., Forma A., Chilimoniuk Z., Dobosz M., Teresiński G., Buszewicz G. et al. Essentiality of trace elements in pregnancy, fertility, and gynecologic cancers-a state-of-the-art Review. Nutrients. 2021;14(1):185. DOI: 10.3390/nu14010185
4. Meixner E., Sandrini E., Hoeltgen L., Eichkorn T., Hoegen P., König L., Arians N. et al. Return to work, fatigue and cancer rehabilitation after curative radiotherapy and radiochemotherapy for pelvic gynecologic cancer. Cancers (Basel). 2022;14(9):2330. DOI: 10.3390/cancers14092330
5. Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018;68(4):284–296. DOI: 10.3322/caac.21456
6. Piechocki M., Koziołek W., Sroka D., Matrejek A., Miziołek P., Saiuk N. et al. Trends in incidence and mortality of gynecological and breast cancers in Poland (1980–2018). Clin. Epidemiol. 2022;14:95– 114. DOI: 10.2147/CLEP.S330081
7. Borgfeldt C., Holmberg E., Marcickiewicz J., Stålberg K., Tholander B., Lundqvist E.Å. et al. Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) study. BMC Cancer. 2021;21(1):658. DOI: 10.1186/s12885-021-08289-3
8. Danckwardt S., Hentze M.W., Kulozik A.E. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J. Mol. Med. (Berl). 2013;91(11):1257–71. DOI: 10.1007/s00109-013-1074-5
9. Kansuttiviwat C., Niprapan P., Tantiworawit A., Norasetthada L., Rattarittamrong E., Rattanathammethee T. et al. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLoS One. 2023;18(1):e0279450. DOI: 10.1371/journal.pone.0279450
10. Ward M., O’Toole S., Abu Saadeh F., Marchocki Z., Ibrahim E., Martin F. et al. Mechanisms of cancer associated thrombosis in gynaecological cancer patients-tumour or treatment effect? [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/mechanisms-of-cancer-associated-thrombosis-in-gynaecologicalcancer-patients-tumour-or-treatment-effect/. Accessed April 20, 2024.
11. Menter D.G., Tucker S.C., Kopetz S., Sood A.K., Crissman J.D., Honn K.V. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231–69. DOI: 10.1007/s10555-014-9498-0
12. Ward M., Kane L., Lochrin S., Ovaere C., O’Gorman C., O’Connor R. et al. Platelet and immune cell cloaking of circulating tumour cells [CTCs] in breast and ovarian cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/platelet-and-immune-cellcloaking-of-circulating-tumour-cells-ctcs-in-breast-and-ovariancancer/. Accessed April 20, 2024.
13. Canonico M.E., Santoro C., Avvedimento M., Giugliano G., Mandoli G.E., Prastaro M. et al. Venous thromboembolism and cancer: A comprehensive review from pathophysiology to novel treatment. Biomolecules. 2022;12(2):259. DOI: 10.3390/biom12020259
14. Kim A.S., Khorana A.A., McCrae K.R. Mechanisms and biomarkers of cancer-associated thrombosis. Transl. Res. 2020;225:33–53. DOI: 10.1016/j.trsl.2020.06.012
15. Darwish I., Kantarcioglu B., Darki A., Siddiqui F., Iqbal O., Hoppensteadt D., Fareed J. The role of selectins in development of acute pulmonary embolism in cancer patients. [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-role-ofselectins-in-development-of-acute-pulmonary-embolism-in-cancerpatients/. Accessed April 20, 2024
16. Menter D.G., Afshar-Kharghan V., Shen J.P., Martch S.L., Maitra A., Kopetz S., Honn K.V., Sood A.K. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev. 2022;41(1):147–172. DOI: 10.1007/s10555-022-10019-5
17. Hisada Y., Geddings J.E., Ay C., Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J. Thromb. Haemost. 2015;13(8):1372–82. DOI: 10.1111/jth.13009
18. Schwameis R., Grimm C., Brodowicz T., Petru E., Hefler-Frischmuth K., Staudigl C.et al. Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma. Sci. Rep. 2016;6:33757. DOI: 10.1038/srep33757
19. Oto J., Mc Cormack B., Tomás-Pérez S., Fernández-Pardo A., González-Cantó E., Cana F.et al. Neutrophil activation markers as novel biomarkers for advanced stages of high-grade serous ovarian cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/neutrophil-activation-markers-as-novel-biomarkers-foradvanced-stages-of-high-grade-serous-ovarian-cancer/. Accessed April 20, 2024.
20. Shinn E.H., Lenihan D.J., Urbauer D.L., Basen-Engquist K.M., Valentine A., Palmero L. et al. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013;22(11):2102–9. DOI: 10.1158/1055-9965.EPI-13-0625
21. Barber E.L., Clarke-Pearson D.L. Prevention of venous thromboembolism in gynecologic oncology surgery. Gynecol. Oncol. 2017; 144(2):420-427. DOI: 10.1016/j.ygyno.2016.11.036
22. Wiegers H., Beenen L., Schaafsma M., Middeldorp S., Hutten B., Mom S., Scheres L. Pre-surgical ovarian vein thrombosis in women with ovarian malignancies as predictor of pulmonary embolism [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/pre-surgical-ovarian-vein-thrombosis-in-women-withovarian-malignancies-as-predictor-of-pulmonary-embolism/. Accessed April 20, 2024.
23. Sermsathanasawadi N., Thangrod R., Hongku K., Wongwanit C., Ruangsetakit C., Chinsakchai K. et al. Prevalence of perioperative asymptomatic proximal deep vein thrombosis in Thai gynecologic cancer patients. J. Med. Assoc. Thai. 2014;97(2):153–8. PMID: 24765892.
24. Kong T.W., Ryu H.S., Kim S.C., Enomoto T., Li J., Kim K.H. et al. Asian Society of Gynecologic Oncology International Workshop 2018. J. Gynecol Oncol. 2019;30(2):e39. DOI: 10.3802/jgo.2019.30.e39
25. Matsuo K., Hasegawa K., Yoshino K., Murakami R., Hisamatsu T., Stone R.L. et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur. J. Cancer. 2015;51(14):1978–88. DOI: 10.1016/j.ejca.2015.07.012
26. Shah S., Dhamane A., Ferri M., Bruette R., Noxon V., Liu X., Jiang J., Luo X.. Factors associated with anticoagulant treatment initiation among venous thromboembolism patients with cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/factors-associated-with-anticoagulant-treatment-initiationamong-venous-thromboembolism-patients-with-cancer/. Accessed April 20, 2024.
27. Zhang W., Liu X., Cheng H., Yang Z., Zhang G. Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China. Medicine (Baltimore). 2018;97(31):e11754. DOI: 10.1097/MD.0000000000011754
28. Guman N., Wiegers H., Schaafsma M., Mulder F., Mom S., van Es N. Performance of the Thrombogyn and Khorana scores for prediction of venous thromboembolism in ovarian cancer patients after major surgery [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/performance-of-the-thrombogyn-and-khorana-scoresfor-prediction-of-venous-thromboembolism-in-ovarian-cancerpatients-after-major-surgery/. Accessed April 20, 2024.
29. Donadini M., Squizzato A., Ferrazzi P., Maggioni S., Sacco C., Lodigiani C. Pharmacological thromboprophylaxis to prevent venous thromboembolism in ambulatory patients with cancer undergoing antineoplastic drugs in real world clinical practice: a cohort study [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/pharmacological-thromboprophylaxis-to-prevent-venousthromboembolism-in-ambulatory-patients-with-cancer-undergoingantineoplastic-drugs-in-real-world-clinical-practice-a-cohort-study/. Accessed April 20, 2024.
30. Vivas Y., Medina E., Abreu E., Rezende S., RIbeiro D. Khorana score as a predictor of thrombotic risk in outpatients with malignant neoplasms [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/khorana-score-as-a-predictor-of-thrombotic-riskin-outpatients-with-malignant-neoplasms/. Accessed April 20, 2024.
31. Lyman G.H., Carrier M., Ay C., Di Nisio M., Hicks L.K., Khorana A.A. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974. DOI: 10.1182/bloodadvances.2020003442
32. Liu M., Wang G., Li Y., Wang H., Liu H., Guo N. et al. Effi cacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 2020;12:1758835920907540. DOI: 10.1177/1758835920907540
33. Park J.Y. The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer. .J Gynecol. Oncol. 2020;31(1):e40. DOI: 10.3802/jgo.2020.31.e40
34. Muñoz Martín A.J., Font Puig C., Navarro Martín L.M., Borrega García P., Martín Jiménez M.; Spanish Society for Medical Oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin. Transl. Oncol. 2014;16(12):1079–90. DOI: 10.1007/s12094-014-1238-y
35. Pachón V., Trujillo-Santos J., Domènech P., Gallardo E., Font C., González Porras J.R. et al. Cancer-associated thrombosis: beyond clinical practice guidelines-a multidisciplinary (SEMI-SEOMSETH) Expert Consensus. TH Open. 2018;2(4):e373–e386. DOI: 10.1055/s-0038-1675577
36. Baaten C.C.F.M.J., Moenen F.C.J.I., Henskens Y.M.C., Swieringa F., Wetzels R.J.H., van Oerle R., Heijnen H.F.G. et al. Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy. Hae ma tologica. 2018;103(9):1557–1567. DOI: 10.3324/haematol.2017.185165
37. Yuk J.S., Lee B., Kim K., Kim M.H., Seo Y.S., Hwang S.O. et al. Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a populationbased study. BMC Cancer. 2021;21(1):1166. DOI: 10.1186/s12885-021-08853-x
38. Wright J.D., Chen L., Jorge S., Burke W.M., Tergas A.I., Hou J.Y. et al. Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecol. Oncol. 2016; 141(3):531–537. DOI: 10.1016/j.ygyno.2016.03.023
39. Faruqi U., Darroch R., Verma H., Bahra G., Flynn M., Danaee A. The role of anticoagulation in the management of tumour thrombosis: A single centre retrospective study [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-role-of-anticoagulation- in-the-management-of-tumour-thrombosis-a-single-centreretrospective-study/. Accessed April 20, 2024.
40. Osataphan S., Patell R., Chiasakul T., Khorana A.A., Zwicker J.I. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv. 2021;5(8):2055– 2062. DOI: 10.1182/bloodadvances.2020004118
41. Ghenassia-Fouillet L., Morel A, Frappé P., Le Hello C., Lerche V., Sevestre M.A., Bertoletti L. Management of superficial venous thrombosis in unevaluated situations: cancer, severe renal impairment, pregnancy and post-partum. Phlebology. 2021;36(6):464–472. DOI: 10.1177/0268355520982456
42. Poenou G., Toledano E., Helfer H., Plaisance L., Versini E., Diab N., Djennaoui S., Mahe I. Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/anticoagulant-associated-bleeding-riskassessment-model-for-cancer-associated-thrombosis-patients-asystematic-review/. Accessed April 20, 2024.
43. Hirmerová J., Šubrt I., Hajšmanová Z. The prevalence of thrombophilia in patients with cancer associated thromboembolism [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-prevalence-of-thrombophilia-in-patients-with-cancerassociated-thromboembolism/. Accessed April 20, 2024.
44. Haque F., Mnyama N., Adeniyi-zaccheus O., Wells R., Brown V., Maraveyas A. Safety and effi cacy of direct oral anticoagulant in elderly patients with cancer: real-world challenges [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/safetyand-efficacy-of-direct-oral-anticoagulant-in-elderly-patients-withcancer-real-world-challenges/. Accessed April 20, 2024.
45. Murofushi K.N., Tomita T., Ohnishi K., Nakai K., Akiyama A., Saida T. et al. Risk factors for venous thromboembolism induced by prolonged bed rest during interstitial brachytherapy for gynecological cancer: a retrospective study. Radiat. Oncol. 2021;16(1):121. DOI: 10.1186/s13014-021-01840-3
46. HinchcliffE.M., Bednar E.M., Lu K.H., Rauh-Hain J.A. Disparities in gynecologic cancer genetics evaluation. Gynecol. Oncol. 2019;153(1):184–191. DOI: 10.1016/j.ygyno.2019.01.024
47. Kostov S., Watrowski R., Kornovski Y., Dzhenkov D., Slavchev S., Ivanova Y., Yordanov A. hereditary gynecologic cancer syndromes — a narrative review. Onco. Targets Ther. 2022;15:381–405. DOI: 10.2147/OTT.S353054
48. Tang Y.H., Lin C.Y., Lai C.H. Development of new cancer treatment by identifying and focusing the genetic mutations or altered expression in gynecologic cancers. Genes (Basel). 2021;12(10):1593. DOI: 10.3390/genes12101593
49. Tang M., Cai J.H., Diao H.Y., Guo W.M., Yang X., Xing S. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum. Vaccin. Immunother. 2022;18(5):2062982. DOI: 10.1080/21645515.2022.2062982
50. Walsh M., Moore E.E., Moore H., Thomas S., Lune S.V., Zimmer D. et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: a review. Semin. Thromb. Hemost. 2019;45(4):354– 372. DOI: 10.1055/s-0039-1688497
51. Siddiqui F., Antic D., Tafur A., Bontekoe E., Hoppensteadt D., Gerotziafas G. et al. Thrombin generation profile in various lymphoma sub-groups and its augmentation by Andexanet Alfa. Clin. Appl. Thromb. Hemost. 2020;26:1076029620983466. DOI: 10.1177/1076029620983466
52. Mauracher L.M., Posch F., Martinod K., Grilz E., Däullary T., Hell L. et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J. Thromb. Haemost. 2018;16(3):508–518. DOI: 10.1111/jth.13951
53. Posch F., Thaler J., Zlabinger G.J., Königsbrügge O., Koder S., Zielinski C., Pabinger I., Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study (CATS). Clin. Cancer Res. 2016;22(1):200–6. DOI: 10.1158/1078-0432.CCR-14-3358. Epub 2015 Aug 24. PMID: 26302981
54. Julia E.G., Nigel M. Recently identified factors that regulate hemostasis and thrombosis. Thromb. Haemost. 2014;111(4):570– 574. DOI:10.1160/TH13-10-0812
Рецензия
Для цитирования:
Мельников А.П., Московкина Е.И., Гасанова К.С. Профилактика тромбозов в онкогинекологии. Клиническая медицина. 2024;102(11-12):824-830. https://doi.org/10.30629/0023-2149-2024-102-11-12-824-830
For citation:
Melnikov A.P., Moskovkina E.I., Gasanova K.S. Prevention of thrombosis in gynecological oncology. Clinical Medicine (Russian Journal). 2024;102(11-12):824-830. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-11-12-824-830
Просмотров:
144
Послать статью по эл. почте 